Target intelligence / Profile preview

Fibrin polymerization interface

Molecular classification
Protein-protein interaction site, Structural protein interface
01

Overview

The fibrin polymerization interface represents the critical protein-protein interaction sites responsible for the assembly of fibrinogen into a structural fibrin network (Weisel & Litvinov, 2017). This process is initiated when thrombin cleaves fibrinopeptides A and B from fibrinogen, exposing N-terminal "knobs" (A and B) (Litvinov & Weisel, 2016). These knobs then bind to pre-existing "holes" ('a' and 'b') located in the C-terminal nodules of neighboring fibrin molecules (Mosesson, 2005). The A:a interaction is primarily responsible for the longitudinal growth of protofibrils, while the B:b interaction facilitates lateral association and branching (UniProt P02671). Dysregulation of this assembly process is a hallmark of thrombotic disorders, including deep vein thrombosis and ischemic stroke (StatPearls, 2023). As a therapeutic target, the interface offers a way to inhibit clot formation directly without necessarily inhibiting the enzymatic activity of thrombin or other coagulation factors. Experimental inhibitors, such as GPRP-based peptides, work by competitively occupying the 'a' holes, thereby preventing the formation of the fibrin mesh (PubMed PMID: 16102035). Targeting these specific interfaces is an active area of research for developing next-generation anticoagulants with potentially reduced bleeding risks.

Other names
Knob-hole interaction sitesFibrin-fibrin assembly sitesA-a and B-b interactionsFibrin protofibril interfaces
02

Mechanism of action

Competitive inhibition of the "knob-hole" interactions between fibrin monomers, specifically blocking the binding of N-terminal "knobs" (exposed by thrombin cleavage) to the C-terminal "holes" in the gamma and beta nodules (Weisel & Litvinov, 2017).

03

Biological functions

Blood coagulationHemostasisFibrin clot formationWound healing
04

Disease associations

ThrombosisCardiovascular diseaseStrokePulmonary embolismDisseminated intravascular coagulation
05

Safety considerations

Risk of hemorrhageImpaired wound healingPotential for incomplete clot formation leading to embolization
06

Interacting drugs

Gly-Pro-Arg-Pro (GPRP) peptide

2 more in the full profile.

07

Biomarkers

D-dimerFibrinogen levelsSoluble fibrin monomerThrombin-antithrombin (TAT) complex

Beyond the preview

Go deeper on Fibrin polymerization interface.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fibrin polymerization interface.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call